Novavax, Inc. (NVAX)
NASDAQ: NVAX · Real-Time Price · USD
6.41
0.00 (0.00%)
At close: May 2, 2025, 4:00 PM
6.43
+0.02 (0.31%)
After-hours: May 2, 2025, 6:11 PM EDT
Novavax Revenue
In the year 2024, Novavax had annual revenue of $682.16M, down -30.65%. Novavax had revenue of $88.31M in the quarter ending December 31, 2024, a decrease of -69.69%.
Revenue (ttm)
$682.16M
Revenue Growth
-30.65%
P/S Ratio
1.43
Revenue / Employee
$716,557
Employees
952
Market Cap
1.03B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 682.16M | -301.54M | -30.65% |
| Dec 31, 2023 | 983.71M | -998.17M | -50.36% |
| Dec 31, 2022 | 1.98B | 835.58M | 72.89% |
| Dec 31, 2021 | 1.15B | 670.69M | 141.02% |
| Dec 31, 2020 | 475.60M | 456.94M | 2,448.48% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.19B |
| Eli Lilly and Company | 49.00B |
| Thermo Fisher Scientific | 42.90B |
NVAX News
- 1 day ago - Novavax to Report First Quarter 2025 Financial Results on May 8, 2025 - PRNewsWire
- 3 days ago - Novavax Appoints Charles Newton to Board of Directors - PRNewsWire
- 7 days ago - FDA asks Novavax to complete new clinical trial for delayed COVID-19 shot, WSJ reports - Reuters
- 7 days ago - FDA Asks Vaccine Maker to Complete New Clinical Trial for Delayed Covid-19 Shot - WSJ
- 8 days ago - Insight: As FDA delays Novavax' COVID vaccine approval, patients fight back - Reuters
- 9 days ago - Novavax's COVID-19 Vaccine Nears FDA Full Approval, Stock Jumps - Benzinga
- 9 days ago - FDA asks Novavax for commitment on post-approval studies for COVID vaccine - Reuters
- 17 days ago - SHIELD-Utah Study Shows Novavax's COVID-19 Vaccine Induces Lower Reactogenicity Symptoms Compared to mRNA - PRNewsWire